PASG
Passage BIO, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 20 FDA: Passage Bio Reports Updated Interim Data from upliFT-D Tri…
- Apr 21 ▼ 3 downgrades
- May 27 ▼ Passage Bio terminated its research collaboration with Gemma Biother…
- Jun 24 ▼ Passage Bio entered into a definitive all-stock merger agreement wit…
- Jun 24 ▼ Passage Bio filed a definitive all-stock merger agreement to acquire…
- Jun 24 ▼ Passage Bio announced a definitive all-stock merger with Remix Thera…
- Jun 25 ▲ 1 insider buy $206.1K at $4.12
- Aug 31 ▲ Short interest falls 25.8% to 101.6K
- Sep 2 ▲ Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merg…
- Sep 3 ▼ Passage Bio filed an amended S-4 (S-4/A) detailing its proposed reve…
- Oct 8 ▼ Passage Bio (PASG) filed Amendment No. 4 to its S-4 registration sta…
- Oct 30 ▲ Short interest falls 28.1% to 49.6K
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $206.1K at an average $4.12. No open-market sales.
- InstitutionsBEARISH
Q3 2026: 0 added (0 new), 4 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$2.820 → −$3.750 over 90 days.
- Short sellersCOVERING
Short interest −28.1% to 49.6K shares. 4.0 days to cover, ≈1.5% of shares.
- TrendUPTREND
1% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | TRIM | $327.3K |
| UBS Group AG | NEAR_EXIT | $1.9K |
| MORGAN STANLEY | NEAR_EXIT | $1.6K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $233.7K |
| Erste Asset Management GmbH | TRIM | $197.2K |
| UBS Group AG | TRIM | $66.2K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $324.9K |
| UBS Group AG | DOUBLED | $215.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Apr 2026Price is below the lowest target. Median implies +275%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Apr 21, 2026 | TD Cowen DOWNGRADE | Hold |
| Apr 21, 2026 | Chardan Capital DOWNGRADE | Neutral |
| Apr 21, 2026 | Oppenheimer MAINTAIN | Outperform |
| Apr 21, 2026 | Wedbush DOWNGRADE | Neutral |
| Mar 31, 2026 | Oppenheimer INITIATE | Outperform |
| Mar 4, 2026 | Canaccord Genuity MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Lynx1 Capital Management LP 10%+ Owner Jun 25, 2026 | BUY | $206.1K |
Countouriotis Athena Director May 19, 2026 | AWARD | 10,539 sh |
GOWEN MAXINE Director May 19, 2026 | AWARD | 10,539 sh |
Kapadia Sandip Director May 19, 2026 | AWARD | 10,539 sh |
Porter Derrell Director May 19, 2026 | AWARD | 10,539 sh |
Kassberg Thomas Richard Director May 19, 2026 | AWARD | 10,539 sh |
Sondhi Dolan Director May 19, 2026 | AWARD | 10,539 sh |
Chou William PRESIDENT AND CEO Mar 16, 2026 | AWARD | 58,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$3.75 | -$3.75–-$3.75 | -33.0% | $0.00 |
| Next Q | -$2.33 | -$4.06–-$1.01 | -20.8% | $0.00 |
| Current FY | -$14.08 | -$14.08–-$14.08 | -24.2% | $0.00 |
| Next FY | -$11.55 | -$11.55–-$11.55 | -11.2% | $0.00 |
Short side
FINRA· Oct 30, 2026| Nov 6, 2026 | Volatility Pause | Resumed |
SecBot reports
13 filings · 2 press releases · 1 bullish · 6 bearish · 1 mixed · 5 neutral- NEUTRAL 8-KNov 6, 2026
Passage Bio stockholders approved all proposals related to the reverse merger with Remix…
All stockholder approvals for the reverse merger have been obtained. The next catalyst is the closing of the merger, which is contingent on remaining conditions. Monitor for the closing announcement…
- NEUTRAL EFFECTOct 13, 2026
Passage BIO's registration statement on Form S-4 (File No. 333-297601) was declared effective by…
The S-4 effectiveness signals that Passage BIO is moving forward with a merger or exchange transaction. Monitor for the definitive proxy/prospectus or transaction announcement, which will reveal the…
- BEARISH S-4/AOct 8, 2026
Passage Bio (PASG) filed Amendment No. 4 to its S-4 registration statement for the proposed…
The merger is a reverse shell transaction where Remix is effectively acquiring Passage Bio's public listing. Existing PASG holders face extreme dilution (~6% pro forma). The CVRs are speculative and…
- NEUTRAL S-4/AOct 5, 2026
Passage Bio filed Amendment No. 3 to its S-4 registration statement for the proposed reverse…
Monitor the Passage Bio special meeting on November 5, 2026, for stockholder approval of the merger proposals. The key catalyst is the closing of the merger and Concurrent Financing, which will…
All PASG filing & press-release reports (15)
- 8-K reportNov 6, 2026
- EFFECT reportOct 13, 2026
- S-4/A reportOct 8, 2026
- S-4/A reportOct 5, 2026
- S-4/A reportSep 21, 2026
- S-4/A, 425 reportSep 2, 2026
- 8-K reportSep 2, 2026
- 8-K reportJun 24, 2026
- 425 reportJun 24, 2026
- 425 reportJun 24, 2026
- 8-K reportMay 27, 2026
- 8-K reportApr 20, 2026
- PRESS-RELEASE reportApr 20, 2026
- DEFA14A reportApr 7, 2026
- PRESS-RELEASE reportMar 3, 2026